-

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Raymond James 47th Annual Institutional Investors Conference
Monday, March 2, 2026
7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

TD Cowen 46th Annual Health Care Conference
Tuesday, March 3, 2026
2:30 p.m. ET - Prahlad Singh, president and chief executive officer

Barclays 28th Annual Global Healthcare Conference
Tuesday, March 10, 2026
10:30 a.m. ET - Prahlad Singh

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Contacts

Investor Relations
Steve Willoughby
steve.willoughby@revvity.com

Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Revvity

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Investor Relations
Steve Willoughby
steve.willoughby@revvity.com

Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com

More News From Revvity

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird’s 2026 Global Healthcare Conference Tuesday, September...

Revvity Announces Financial Results for the Second Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related...
Back to Newsroom